XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...

Indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter First pathogen-targeted therapy ...

Scientists in Switzerland have announced the discovery of a new class of antibiotics shown to be effective against deadly, drug-resistant bacteria. The antibiotic, called zosurabalpin, works by ...

Jaipur: A study conducted by SMS Medical College has raised alarm bells as it reveals a significant rise in antibiotic resistance among Acinetobacter bacteria infections. The research, which analysed ...

Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...

The amphipathic lipopolysaccharides in the outer leaflet of the asymmetric outer membrane bilayer of Gram-negative bacteria block antibiotic entry, making the treatment of bacterial infections ...

A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few ...

Once seen as a lasting medical breakthrough, antibiotics are steadily losing their effectiveness. Around the world, ...